Qiagen (QGEN) Projected to Post Quarterly Earnings on Wednesday

Qiagen (NYSE:QGEN) is projected to issue its quarterly earnings data after the market closes on Wednesday, February 5th. Analysts expect the company to announce earnings of $0.60 per share and revenue of $518.54 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Qiagen Trading Down 0.7 %

Shares of QGEN stock opened at $45.15 on Wednesday. The stock has a 50 day simple moving average of $44.77 and a 200 day simple moving average of $44.37. Qiagen has a 1 year low of $39.03 and a 1 year high of $47.93. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. The stock has a market cap of $10.30 billion, a P/E ratio of 115.78, a price-to-earnings-growth ratio of 3.49 and a beta of 0.37.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on QGEN shares. Jefferies Financial Group restated a “buy” rating and set a $54.00 price target (up from $42.00) on shares of Qiagen in a report on Tuesday, December 10th. HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a report on Thursday, October 17th. Morgan Stanley reaffirmed an “equal weight” rating and set a $48.00 price target (down previously from $50.00) on shares of Qiagen in a research note on Monday, January 6th. Finally, Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $51.50.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.